Young Lung Cancer Initiative Podcast
In lung cancer, HER2 can mean different things. In Part 1 of our HER2-driven lung cancer series, Leah Phillips sits down with thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) to cover the basics: what a HER2 alteration actually is, the difference between overexpression, amplification, and the exon 20 insertion mutation, why the type matters for treatment, and why next-generation sequencing at diagnosis is non-negotiable. This is Part 1 of 3. Parts 2 and 3 cover treatment and monitoring, then resistance and emerging research. About Dr. Kyle Concannon: Assistant Professor of Medicine-Medical Oncology at the University of Colorado and a thoracic medical oncologist at UCHealth University of Colorado Hospital. Trained as a physician-scientist at MD Anderson, his lab studies why oncogene-driven lung cancers (EGFR, HER2, ALK, ROS1) stop responding to therapy and how to overcome that resistance. He also co-hosts The @crackingcancer podcast [https://studio.youtube.com/channel/UCFJwUDDzRTkv81Nq8PEuJ3A] https://som.cuanschutz.edu/Profiles/Faculty/Profile/40545 [https://som.cuanschutz.edu/Profiles/Faculty/Profile/40545] This series is proudly sponsored by Boehringer Ingelheim. This is educational content. Not medical advice. Always talk to your own care team about your specific situation.
27 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Young Lung Cancer Initiative Podcast!